Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.
A new community-led network called PRADA enables underrepresented patients living with MS to help set research priorities.
Merck and Mayo Clinic are partnering to use AI technology and large-scale clinical data to speed drug development in MS and ...
Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when ...
Columnist Ben Hofmeister may rely on others for daily living, but trusting people isn't the same as giving up, he says.
UCSF is teaming up with Nektar to study NKTR-0165, an experimental antibody that activates the TNFR2 receptor, as a treatment ...
Breastfeeding for longer in infancy may be associated with lower disease severity and a later onset of MS in adulthood, a ...
A collaboration will test whether changes in a person’s voice can help detect multiple sclerosis, potentially enabling a ...
Immunic raised funds to support Phase 3 clinical trials of vidofludimus calcium for MS and transition into a commercial-stage company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results